About us

Our goal is to translate scientific advances in RNA Nanotechnology to improve the therapeutic outcomes and lives of our patients

ExonanoRNA is a platform biotechnology company developing a new class of RNA nanotechnology-based therapeutics for cancer treatment. Our proprietary RNA NanoParticles (RNP) are designed to unlock the potential of RNA therapeutics in a range of cancer disease treatment. RNA Nanotechnology enables cancer cell-specific delivery of siRNA, miRNA, and chemo drugs with significantly enhanced efficacy and reduced toxicity. Our pharmaceutical R&D focuses on addressing treatment for late-stage oncology diseases.

What We Do

Pharmaceutical R&D

Products and Services for RNA Nanotechnology

Pharmaceutical R&D

RNA NanoParticle Delivery System (RNP)

Our RNA NanoParticle Delivery System (RNP) creates a unique nano-scaffold conjugated with small therapeutic RNA molecules and chemotherapeutic drugs that result in extraordinary pharmacokinetic and pharmacodynamic properties.
RNA NANOPARTICLE (RNP) PLATFORM:

  • The negative charge of RNP prevents nonspecific binding to cells
  • The defined structure and size (10-40nm) avoids immune system clearance
  • Targets tumors through enhanced permeability and retention (EPR) effect and by active targeting of ligands on RNP
  • Favorable PK profiles in mice:
    • T1/2: 5-10hr compared to 0.25-0.76hr of siRNA
    • Biodistribution: mainly in the tumor but no other healthy organs.
  • High delivery efficiency: ~5% compared to 0.7% using other nanoparticles
  • Low toxicity: no toxicity after repeated IV up to 30mg/kg in mice
  • Low immunogenicity: does not induce interferon or cytokine responses
RNA 4WJ Model

RNA Nanoparticles Displaying Exosomes Delivery System (ExRNA)

ExRNA exosomes deliver nucleic acid-based therapeutics to treat life-threatening diseases. We harnessed the natural delivery capabilities of exosomes and specific targeting properties of RNA nanoparticles to create a novel class of biotherapeutics.
ExRNA PLATFORM:

  • Displaying RNA nanoparticles on the exosome’s surface makes the ExRNA negatively charged, which prevents nonspecific binding to cells.
  • Displaying RNA nanoparticles with an aptamer or chemical ligand enhances its targeting efficiency.
  • ExRNA effectively delivers siRNA to the cell cytoplasm, escaping endosome trapping
  • Validated in mouse model systems
Exosome Diagram
OUR TEAM

Peixuan Guo, PhD
Founder, Board Director, Chairman of Scientific Advisory Committee

Michael Li MD, PhD
VP, Board Director

Gary Li MD
Board Director

Footer-img
Logo